Syngenta logo

Syngenta

Last updated January 31, 2026
86
Innovation Areas
1,941
Inventors
49
Collaborations

Asymmetric isoxazoline synthesis catalysis: SyngentaRecent Research Landscape

Uncontrolled chirality in small molecule synthesis leads to low pharmacological potency and high purification costs. These innovations utilize specific catalytic pathways to ensure precise enantiomeric and diastereomeric enrichment.

What technical problems is Syngenta addressing in Asymmetric isoxazoline synthesis catalysis?

Low regioselectivity in complex substitutions

(10)evidences

Uncontrolled substitution patterns during the synthesis of complex arenes lead to poor isomeric purity. Achieving precise site-selectivity reduces waste and simplifies downstream purification in multi-step synthesis.

Sulfur stereocenter configuration instability

(8)evidences

Inconsistent configuration at the sulfur atom during synthesis leads to racemic mixtures. Precise stereogenic control enables the production of enantiopure bioactive molecules.

Low enantiomeric product purity

(5)evidences

Inconsistent spatial arrangement of atoms during synthesis leads to ineffective isomers. Achieving high enantiomeric or diastereomeric excess ensures biological activity and reduces chemical waste.

Low stereochemical purity

(3)evidences

Insufficient control over enantiomeric and diastereomeric ratios during synthesis leads to chemical waste and reduced biological activity. Achieving high isomeric enrichment ensures precise molecular targeting and regulatory compliance.

Low chiral purity yields

(3)evidences

The synthesis of oxime derivatives often results in racemic mixtures or insufficient optical enrichment. Achieving high enantiomeric excess is critical for the biological efficacy and safety of pharmaceutical compounds.